In this article, we will take a look at some of the best stocks under $10 that currently offer an upside potential of at least 200%.

On July 2, Dominic Pappalardo, Chief Multi-Asset Strategist at Morningstar Wealth, shared his views on small-cap stocks, which are projected to sustain their above-market performance as valuations stay appealing relative to large-cap shares. In the midst of a volatile year, both Latin American and small-cap stocks have been rising since the start of the war in the Iran-U.S. conflict.

Pappalardo highlighted that during 2026, the Morningstar U.S. Small Cap Market Index has increased 14%, compared to a 10.7% jump for the Morningstar U.S. Market. He believes that the increase in small-caps has the strength to persist, given that U.S. small-cap stocks have underperformed their mid- and large-cap peers over the past 15 years.

He also noted that the small-cap group offers greater diversification relative to large caps, citing the S&P 500, which has 40% of its underlying composition concentrated in 10 names.

Morningstar Wealth believes that small-cap stocks appear more undervalued than they have in a long time, while large caps currently appear overvalued.

With that background, let’s explore our 10 Best Stocks Under $10 That Could Triple.

Our Methodology

To identify relevant stocks for this article, we screened U.S.-listed companies with market capitalizations above $2 billion. Also, we only shortlisted stocks with at least 200% upside potential, according to consensus, as of the July 10 close. Finally, we selected 10 stocks with the highest upside and ranked them in ascending order.

Why are we interested in the stocks that hedge funds pile into? The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds. Our quarterly newsletter’s strategy selects 14 small-cap and large-cap stocks every quarter and has returned 599.2% since May 2014, beating its benchmark by 372 percentage points (see more details here).

10. Verastem Inc. (NASDAQ:VSTM)

Verastem Inc. (NASDAQ:VSTM) is one of the 10 best stocks under $10 that could triple.

On July 7, RBC Capital maintained its Outperform rating on Verastem Inc. (NASDAQ:VSTM). The firm reduced the target price from $15 to $14, which still offers a revised upside potential of over 211%. The price target adjustment accompanies the firm’s broader biotech sector earnings preview for the second quarter.

RBC Capital highlighted the sector’s notable momentum during June, including a 2-week rally outpacing the S&P. This was supported by encouraging data around innovations, as well as a favorable sentiment regarding the FDA’s flexible stance.

The firm expects capital inflows to persist as the sector’s outlook offers more visibility compared to others. It acknowledged strong second quarter earnings across the sector, with more opportunities to achieve earnings beats, and maintains that the ongoing M&A activity is likely to offer more support.

Back on June 23, Verastem Inc. (NASDAQ:VSTM) revealed encouraging preliminary results from the company’s Phase 1/2 trial for the TARGET-D 101 study of VS-7375. It is an investigational oral inhibitor that targets KRAS G12D in patients with late-stage KRAS G12D-mutated tumors.

Results indicated promising clinical activity with a sound tolerability and safety profile across several tumor types and dosage levels. The tumors include advanced non-small cell lung cancer, metastatic colorectal cancer, and metastatic pancreatic ductal carcinoma.

Verastem Inc. (NASDAQ:VSTM) is a development-stage biopharmaceutical company involved in developing and commercializing drugs for the treatment of cancer. Its product candidates are Avutometinib, FAKZYNJA, Defactinib, VS-7375, CO-PACK, and AVMAPKI. The company is involved in clinical studies of RAMP 301, RAMP 205, FRAME, VS-7375-101, RAMP 203, and RAMP 201.

9. Sable Offshore Corp. (NYSE:SOC)

Sable Offshore Corp. (NYSE:SOC) is one of the 10 best stocks under $10 that could triple.

On July 6, Lloyd Byrne from Jefferies reduced Sable Offshore Corp.’s (NYSE:SOC) price target from $24 to $11. Despite such a huge downward adjustment, the price target still results in an upside potential of over 180%.

The analyst maintained a Buy rating on the stock despite some recent challenges, such as the dilution for current equity holders caused by the recent convertible notes offering. The offering was executed amid the company’s failure to attain government support.

Earlier on July 1, Sable Offshore Corp. (NYSE:SOC) shared details around the company’s recent public offerings. These involved 32,467,533 common shares, priced at $3.08 per share, and the issuance of 6.5% convertible senior notes with a $300 million principal amount due in 2031.

The company offered underwriters a one-month period to purchase up to an additional 4,870,129 common shares and up to $45 million in additional notes, with the aim of covering excess allotments. The notes will fall under senior unsecured liabilities, accruing interest at 6.5% per year, that will be payable on a semi-annual basis.

The starting conversion rate is 249.7502 shares per $1,000 face value, with an estimated conversion price of $4 per share. This leads to a premium of about 30% over the public offering rate.

Sable Offshore Corp. (NYSE:SOC) is an oil and gas production company that conducts independent exploration, production, and marketing. In addition, the company operates a subsea pipeline that transports oil, gas, and produced water to the processing plants.

8. Larimar Therapeutics Inc. (NASDAQ:LRMR)

Larimar Therapeutics Inc. (NASDAQ:LRMR) is one of the 10 best stocks under $10 that could triple.

On June 29, Larimar Therapeutics Inc. (NASDAQ:LRMR) filed the first module of its Biologics License Application (BLA) to the U.S. FDA to get its Nomlabofusp therapy approved on an accelerated basis.  The company also plans to submit the other modules during the second half of 2026.

In addition, Larimar revealed that the Nomlabofusp therapy had exhibited positive outcomes in an open-label study involving adult patients receiving daily injections to treat Friedreich’s ataxia.

According to the President and CEO, Carole Ben-Maimon, the new data is an important step in the development of the latest treatment method. It had been confirmed by the FDA that the existing data is enough to approve the application since it is based on skin frataxin, which is a new surrogate endpoint.

Later, on June 30, Christopher Chen from Baird reduced his target price for the stock from $7 to $5, which still offers more than 53% upside potential at the prevailing level. The analyst reiterated his Outperform rating on the stock, based on revisions to the firm’s model.

These revisions came at the back of the company’s Nomlabofusp therapy updates, indicating clinical benefits yet carrying certain safety concerns.

Larimar Therapeutics Inc. (NASDAQ:LRMR) is a clinical-stage biotechnology company that focuses on finding cures for rare illnesses through its innovative cell-penetrating peptide technology platform. Its primary candidate is CTI-1601, which is currently undergoing Phase 2 OLE trials in order to reach a cure for Friedreich’s ataxia.

7. AtaiBeckley N.V. (NASDAQ:ATAI)

AtaiBeckley N.V. (NASDAQ:ATAI) is one of the 10 best stocks under $10 that could triple.

On June 25, AtaiBeckley N.V. (NASDAQ:ATAI) shared that the company will be included in the Russell indices following their latest reconstitution. The stock will become a part of the small-cap focused Russell 2000 Index, as well as the broader Russell 3000 Index, effective from June 29 onwards.

The company highlighted this as a significant development since more than $12 trillion worth of assets are benchmarked relative to the Russell indexes. The Russell 2000 Index tracks around 2,000 small-cap stocks, while the Russell 3000 Index covers around 3,000 small-, mid-, and large-cap stocks.

Later on July 7, Canaccord Genuity increased the price target on AtaiBeckley N.V. (NASDAQ:ATAI) from $15 to $17, resulting in an adjusted upside potential of over 227%. The firm also reiterated its Buy rating on the stock.

The price target revision came after the company revealed that it has concluded dosing for the final patient in relation to its Phase 2 Elumina trial of VLS-01 for treatment-resistant depression. The company is targeting Phase 3 development for major depressive disorder, with a possibility of expanding into generalized anxiety disorder.

AtaiBeckley N.V. (NASDAQ:ATAI) is a clinical-stage biopharmaceutical company involved in the research, development, and commercialization of mental health therapies. The company’s product pipeline consists of BPL-003 undergoing Phase 2 trials for treatment-resistant depression and alcohol addiction, as well as RL-007 being developed for cognitive decline from schizophrenia.

6. SAB Biotherapeutics Inc. (NASDAQ:SABS)

SAB Biotherapeutics Inc. (NASDAQ:SABS) is one of the 10 best stocks under $10 that could triple.

On July 7, SAB Biotherapeutics Inc. (NASDAQ:SABS) and Breakthrough T1D, a leading research and advocacy firm for type 1 diabetes, disclosed that Breakthrough T1D has awarded a research grant to Michael J. Haller, M.D., Chief Pediatric Endocrinologist and Professor at the University of Florida. This grant has been given to support the PRISE-hATG, which is a clinical assessment of SAB-142 in Stage 3 T1D patients, who are somewhere between 100 days and 2 years away from disease diagnosis.

This study aims to evaluate whether SAB-142 has the capability to preserve endogenous C-peptide and regulate immune responses. It applies to individuals who carry residual beta cell activity after the initial 100 days following the diagnosis of Stage 3.

Back on June 24, Eliana Merle from Barclays initiated coverage of the stock with an Overweight rating. She set a target price of $13, which translates into an upside potential of more than 240% at the current level.

Merle noted that SAB-142 carries a lucrative opportunity as a disease-altering cure for type 1 diabetes. Going forward, she is anticipating the immunotherapy’s Phase 2b data to be a key catalyst for the stock, with results expected sometime during the second half of 2027.

SAB Biotherapeutics Inc. (NASDAQ:SABS) is a clinical-stage biopharmaceutical company that focuses on the development of human polyclonal immunotherapeutic antibodies. Its main product candidate is SAB-142 for the treatment of autoimmune type 1 diabetes in Phase 2b clinical trials.

Click to continue reading and see the 5 Best Stocks Under $10 That Could Triple.

Disclosure: None. Follow Insider Monkey on Google News.